Almorexant
A dual Orexin receptor OX1/OX2 antagonist with Ki of 1.3/0.17 nM for hOX1/hOX2 respectively; selectively inhibits the functional consequences of OX1 and OX2 receptor activation, such as intracellular Ca2+ mobilization.Sleep Disorder Phase 3 Discontinued (In Vitro) :Almorexant (1 μM) promotes tyrosine phosphorylation of SHP2/OX1R complex.Almorexant (1 μM) inhibits the cellular growth of AsPC-1 cells. (In Vivo) :Almorexant (1.8 μmol/kg, 100 μL; IP, daily) reduces the volume of tumors.Almorexant (300 mg/kg, PO, once) can help rats to be fully capable of spatial and avoidance learning.Almorexant (30-300 mg/kg) dose-dependently increases rapid eye movement (REM) and non-REM (NREM) sleep and decreases wakefulness apparently without inducing either cataplexy18 or deficits in next-day performance.
Product Specifications
CAS Number
871224-64-5
Product Name Alternative
ACT-078573 | ACT 078573 | ACT078573
Purity
>98% (HPLC)
Solubility
10 mM in DMSO
Smiles
CNC (=O) [C@H] (N1CCc2cc (OC) c (OC) cc2[C@@H]1CCc3ccc (cc3) C (F) (F) F) c4ccccc4
Molecular Formula
C29H31F3N2O3
Molecular Weight
512.5632
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2 (1H) -Isoquinolineacetamide, 3,4-dihydro-6,7-dimethoxy-N-methyl-α-phenyl-1-[2-[4- (trifluoromethyl) phenyl]ethyl]-, (αR,1S) -
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Olr624 CRISPRa sgRNA lentivector (set of three targets)(Rat)
Recombinant Staphylococcus aureus Signal peptidase IB (spsB), partial
Recombinant Staphylococcus aureus Signal peptidase IB (spsB), partial